To evaluate the MUC1-associated metabolic reprogramming in sunitinib responsive patients, untargeted metabolomic analysis was performed on 30 primary ccRCC derived from metastatic patients treated with sunitinib, and including MUC1H-CR (n = 10), MUC1L-PD (n = 10), and MUC1neg-PD. Here, MUC1 is linked to nonpapillary renal cell carcinoma.